Literature DB >> 10455299

Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits.

J C Verd1, C Peris, M Alegret, C Díaz, G Hernández, M Vázquez, T Adzet, J C Laguna, R M Sánchez.   

Abstract

The effects of atorvastatin (3 mg kg(-1)) and simvastatin (3 mg kg(-1)) on hepatic enzyme activities involved in very low density lipoprotein metabolism were studied in coconut oil/cholesterol fed rabbits. Plasma cholesterol and triglyceride levels increased 19 and 4 fold, respectively, after 7 weeks of feeding. Treatment with statins during the last 4 weeks of feeding abolished the progression of hypercholesterolaemia and reduced plasma triglyceride levels. 3-Hydroxy-3-methyl-glutaryl Coenzyme A reductase, acylcoenzyme A:cholesterol acyltransferase, phosphatidate phosphohydrolase and diacylglycerol acyltransferase activities were not affected by drug treatment. Accordingly, hepatic free cholesterol, cholesteryl ester and triglyceride content were not modified. Simvastatin treatment caused an increase (72%) in lipoprotein lipase activity without affecting hepatic lipase activity. Atorvastatin caused a reduction in hepatic phospholipid content and a compensatory increase in CTP:phosphocholine cytidylyl transferase activity. The results presented in this study suggest that, besides the inhibitory effect on 3-hydroxy-3-methyl-glutaryl Coenzyme A reductase, simvastatin and atorvastatin may have additional effects that contribute to their triglyceride-lowering ability.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10455299      PMCID: PMC1760655          DOI: 10.1038/sj.bjp.0702668

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Choline-phosphate cytidylyltransferase.

Authors:  P A Weinhold; D A Feldman
Journal:  Methods Enzymol       Date:  1992       Impact factor: 1.600

2.  Diacylglycerol acyltransferase and monoacylglycerol acyltransferase from liver and intestine.

Authors:  R A Coleman
Journal:  Methods Enzymol       Date:  1992       Impact factor: 1.600

Review 3.  Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans.

Authors:  J M Dietschy; S D Turley; D K Spady
Journal:  J Lipid Res       Date:  1993-10       Impact factor: 5.922

4.  Lipoprotein(a) plasma concentrations associated with lipolytic activities in eight kindreds with familial combined hyperlipidemia and normolipidemic subjects.

Authors:  M Castro Cabezas; T W de Bruin; M Van Linde-Sibenius Trip; L A Kock; H Jansen; D W Erkelens
Journal:  Metabolism       Date:  1993-06       Impact factor: 8.694

5.  Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.

Authors:  W Qin; J Infante; S R Wang; R Infante
Journal:  Biochim Biophys Acta       Date:  1992-07-09

Review 6.  Comparison of statins in hypertriglyceridemia.

Authors:  E A Stein; M Lane; P Laskarzewski
Journal:  Am J Cardiol       Date:  1998-02-26       Impact factor: 2.778

7.  Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion.

Authors:  M C Cabezas; T W de Bruin; L A Kock; W Kortlandt; M Van Linde-Sibenius Trip; H Jansen; D W Erkelens
Journal:  Metabolism       Date:  1993-04       Impact factor: 8.694

Review 8.  Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells.

Authors:  J L Dixon; H N Ginsberg
Journal:  J Lipid Res       Date:  1993-02       Impact factor: 5.922

Review 9.  HMG-CoA reductase inhibitors: a look back and a look ahead.

Authors:  J Davignon; M Montigny; R Dufour
Journal:  Can J Cardiol       Date:  1992-10       Impact factor: 5.223

10.  Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.

Authors:  T M Bocan; E Ferguson; W McNally; P D Uhlendorf; S Bak Mueller; P Dehart; D R Sliskovic; B D Roth; B R Krause; R S Newton
Journal:  Biochim Biophys Acta       Date:  1992-01-24
View more
  12 in total

1.  Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice.

Authors:  Marleen Schonewille; Jan Freark de Boer; Laura Mele; Henk Wolters; Vincent W Bloks; Justina C Wolters; Jan A Kuivenhoven; Uwe J F Tietge; Gemma Brufau; Albert K Groen
Journal:  J Lipid Res       Date:  2016-06-16       Impact factor: 5.922

2.  Comparative evaluation between chitosan and atorvastatin on serum lipid profile changes in hyperlipidemic cats.

Authors:  B Mosallanejad; R Avizeh; M Razi Jalali; M Pourmahdi
Journal:  Iran J Vet Res       Date:  2016       Impact factor: 1.376

3.  Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4.

Authors:  Elena Sanguino; Nuria Roglans; Marta Alegret; Rosa M Sánchez; Manuel Vázquez-Carrera; Juan C Laguna
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

4.  Lipoprotein lipase HindIII polymorphism influences HDL-cholesterol levels in statin-treated patients with coronary artery disease.

Authors:  Martin Javorský; Daniela Gasperíková; Jozef Ukropec; Barbora Sedláková; Igor Riecanský; Ol'ga Krizanová; Elena Seböková; Martina Dobríková; Iwar Klimes; Ivan Tkác
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

5.  Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1.

Authors:  G Heeba; M E Moselhy; M Hassan; M Khalifa; R Gryglewski; T Malinski
Journal:  Br J Pharmacol       Date:  2009-02-18       Impact factor: 8.739

6.  High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.

Authors:  Núria Roglans; Joan C Verd; Cristina Peris; Marta Alegret; Manuel Vázquez; Tomás Adzet; Cristina Díaz; Gonzalo Hernández; Juan C Laguna; Rosa M Sánchez
Journal:  Lipids       Date:  2002-05       Impact factor: 1.880

7.  Stability Indicating RP-HPLC Estimation of Atorvastatin Calcium and Amlodipine Besylate in Pharmaceutical Formulations.

Authors:  D A Shah; K K Bhatt; R S Mehta; S L Baldania; T R Gandhi
Journal:  Indian J Pharm Sci       Date:  2008-11       Impact factor: 0.975

Review 8.  Statins redux: A re-assessment of how statins lower plasma cholesterol.

Authors:  Rajendra Raghow
Journal:  World J Diabetes       Date:  2017-06-15

9.  Effects of three different formulae of Gamisoyosan on lipid accumulation induced by oleic acid in HepG2 cells.

Authors:  Hiroe Go; Jin Ah Ryuk; Joo Tae Hwang; Byoung Seob Ko
Journal:  Integr Med Res       Date:  2017-09-01

10.  Effects of probiotic bacteria, isoflavones and simvastatin on lipid profile and atherosclerosis in cholesterol-fed rabbits: a randomized double-blind study.

Authors:  Daniela C U Cavallini; Raquel Bedani; Laura Q Bomdespacho; Regina C Vendramini; Elizeu A Rossi
Journal:  Lipids Health Dis       Date:  2009-01-07       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.